Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have been assigned a consensus rating of "Buy" from the nine ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $10.67.
Several research firms have commented on ACRS. Craig Hallum set a $9.00 price target on shares of Aclaris Therapeutics in a research note on Wednesday, October 28th. Wedbush lowered Aclaris Therapeutics from an "outperform" rating to a "neutral" rating and dropped their price objective for the stock from $8.00 to $3.00 in a report on Tuesday. Weiss Ratings restated a "sell (d-)" rating on shares of Aclaris Therapeutics in a research note on Monday, September 21st. Wall Street Zen raised shares of Aclaris Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, October 24th. Finally, Canaccord Genuity Group reduced their target price on Aclaris Therapeutics from $13.00 to $12.00 and set a "buy" rating for the company in a report on Tuesday.
Read Our Latest Analysis on Aclaris Therapeutics
Aclaris Therapeutics Stock Up 3.6%
Shares of ACRS stock opened at $3.50 on Thursday. Aclaris Therapeutics has a 52-week low of $2.34 and a 52-week high of $6.60. The stock has a market cap of $555.13 million, a PE ratio of -6.03 and a beta of 0.96. The business has a 50-day simple moving average of $4.29 and a 200-day simple moving average of $4.53.
Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.04. The company had revenue of $1.48 million during the quarter, compared to analyst estimates of $1.27 million. Aclaris Therapeutics had a negative net margin of 1,244.09% and a negative return on equity of 59.19%. Sell-side analysts anticipate that Aclaris Therapeutics will post -0.56 earnings per share for the current fiscal year.
Institutional Trading of Aclaris Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in ACRS. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Aclaris Therapeutics during the third quarter worth approximately $40,000. MBE Wealth Management LLC acquired a new position in shares of Aclaris Therapeutics in the 3rd quarter valued at about $53,000. Jefferies Financial Group Inc. acquired a new position in Aclaris Therapeutics during the second quarter valued at approximately $58,000. Legal & General Group Plc purchased a new stake in Aclaris Therapeutics during the 2nd quarter worth $61,000. Finally, Walleye Capital LLC acquired a new position in shares of Aclaris Therapeutics during the second quarter worth about $104,000. 98.34% of the stock is currently owned by hedge funds and other institutional investors.
Aclaris Therapeutics Company Profile
(
Get Free Report)
Aclaris Therapeutics is a biopharmaceutical company focused on discovering and developing treatments for immuno-inflammatory diseases. Its research programs include small-molecule therapies designed to target pathways involved in inflammation and immune responses. The company's development portfolio has included candidates for dermatologic and other inflammatory conditions. Aclaris previously developed ESKATA, a topical treatment for raised seborrheic keratoses that received U.S. regulatory approval in 2017.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aclaris Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aclaris Therapeutics wasn't on the list.
While Aclaris Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.